Medical - Pharmaceuticals
Compare Stocks
5 / 10Stock Comparison
BGMS vs DBVT vs ALKS vs GRWG vs HYFM
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Specialty Retail
Agricultural - Machinery
BGMS vs DBVT vs ALKS vs GRWG vs HYFM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Pharmaceuticals | Biotechnology | Biotechnology | Specialty Retail | Agricultural - Machinery |
| Market Cap | $21K | $1713.21T | $6.38B | $82M | $5M |
| Revenue (TTM) | $81K | $0.00 | $1.56B | $162M | $146M |
| Net Income (TTM) | $-5M | $-168M | $153M | $-24M | $-65M |
| Gross Margin | 18.5% | — | 65.4% | 19.8% | 10.2% |
| Operating Margin | -113.2% | — | 12.3% | -15.7% | -35.8% |
| Forward P/E | — | — | 26.8x | — | — |
| Total Debt | $0.00 | $22M | $70M | $29M | $170M |
| Cash & Equiv. | $3M | $194M | $1.12B | $30M | $26M |
BGMS vs DBVT vs ALKS vs GRWG vs HYFM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| DBV Technologies S.… (DBVT) | 100 | 76.3 | -23.7% |
| Alkermes plc (ALKS) | 100 | 191.9 | +91.9% |
| GrowGeneration Corp. (GRWG) | 100 | 3.4 | -96.6% |
| Hydrofarm Holdings … (HYFM) | 100 | 0.2 | -99.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BGMS vs DBVT vs ALKS vs GRWG vs HYFM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BGMS lags the leaders in this set but could rank higher in a more targeted comparison.
DBVT is the #2 pick in this set and the best alternative if momentum is your priority.
- +97.4% vs BGMS's -84.4%
ALKS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -5.2%, EPS growth -34.1%, 3Y rev CAGR 9.9%
- 3.5% 10Y total return vs GRWG's -76.6%
- Lower volatility, beta 1.00, Low D/E 3.8%, current ratio 3.55x
- -5.2% revenue growth vs DBVT's -100.0%
GRWG is the clearest fit if your priority is defensive.
- Beta 1.15, current ratio 3.99x
HYFM ranks third and is worth considering specifically for income & stability.
- Dividend streak 1 yrs, beta 0.73
- Beta 0.73 vs BGMS's 1.88
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | -5.2% revenue growth vs DBVT's -100.0% | |
| Quality / Margins | 9.8% margin vs BGMS's -67.1% | |
| Stability / Safety | Beta 0.73 vs BGMS's 1.88 | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +97.4% vs BGMS's -84.4% | |
| Efficiency (ROA) | 5.4% ROA vs BGMS's -106.7% |
BGMS vs DBVT vs ALKS vs GRWG vs HYFM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
BGMS vs DBVT vs ALKS vs GRWG vs HYFM — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALKS leads in 3 of 6 categories
HYFM leads 2 • BGMS leads 0 • DBVT leads 0 • GRWG leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALKS and DBVT operate at a comparable scale, with $1.6B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to BGMS's -67.1%. On growth, BGMS holds the edge at +7.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $81,000 | $0 | $1.6B | $162M | $146M |
| EBITDAEarnings before interest/tax | -$9M | -$112M | $212M | -$14M | -$23M |
| Net IncomeAfter-tax profit | -$5M | -$168M | $153M | -$24M | -$65M |
| Free Cash FlowCash after capex | -$6M | -$151M | $392M | -$10M | -$8M |
| Gross MarginGross profit ÷ Revenue | +18.5% | — | +65.4% | +19.8% | +10.2% |
| Operating MarginEBIT ÷ Revenue | -113.2% | — | +12.3% | -15.7% | -35.8% |
| Net MarginNet income ÷ Revenue | -67.1% | — | +9.8% | -14.9% | -44.5% |
| FCF MarginFCF ÷ Revenue | -75.2% | — | +25.1% | -6.2% | -5.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.1% | — | +28.2% | +1.0% | -33.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +99.4% | +91.5% | -4.1% | +69.2% | -22.7% |
Valuation Metrics
HYFM leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $20,975 | $1713.21T | $6.4B | $82M | $5M |
| Enterprise ValueMkt cap + debt − cash | -$3M | $1713.21T | $5.3B | $81M | $148M |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -0.76x | 26.78x | -3.42x | -0.07x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 18.97x | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.49x | — | 4.32x | 0.51x | 0.02x |
| Price / BookPrice ÷ Book value/share | — | 0.66x | 3.55x | 0.84x | 0.02x |
| Price / FCFMarket cap ÷ FCF | — | — | 13.29x | — | — |
Profitability & Efficiency
ALKS leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-187 for BGMS. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to HYFM's 0.76x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs BGMS's 1/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -187.3% | -130.2% | +8.8% | -22.9% | -32.3% |
| ROA (TTM)Return on assets | -106.7% | -89.0% | +5.4% | -15.2% | -16.3% |
| ROICReturn on invested capital | — | — | +18.9% | -16.1% | -9.6% |
| ROCEReturn on capital employed | — | -145.7% | +14.2% | -17.9% | -12.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 | 7 | 5 | 3 |
| Debt / EquityFinancial leverage | — | 0.13x | 0.04x | 0.30x | 0.76x |
| Net DebtTotal debt minus cash | -$3M | -$172M | -$1.0B | -$929,000 | $143M |
| Cash & Equiv.Liquid assets | $3M | $194M | $1.1B | $30M | $26M |
| Total DebtShort + long-term debt | $0 | $22M | $70M | $29M | $170M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x | 32.30x | — | -3.77x |
Total Returns (Dividends Reinvested)
ALKS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $17,063 today (with dividends reinvested), compared to $17 for HYFM. Over the past 12 months, DBVT leads with a +97.4% total return vs BGMS's -84.4%. The 3-year compound annual growth rate (CAGR) favors ALKS at 7.1% vs HYFM's -55.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -33.3% | +5.0% | +35.5% | -11.0% | -37.5% |
| 1-Year ReturnPast 12 months | -84.4% | +97.4% | +22.4% | +22.3% | -73.8% |
| 3-Year ReturnCumulative with dividends | -84.4% | +1.0% | +22.9% | -66.1% | -91.0% |
| 5-Year ReturnCumulative with dividends | -84.4% | -66.9% | +70.6% | -96.3% | -99.8% |
| 10-Year ReturnCumulative with dividends | -84.4% | -86.7% | +3.5% | -76.6% | -99.8% |
| CAGR (3Y)Annualised 3-year return | -46.2% | +0.3% | +7.1% | -30.3% | -55.2% |
Risk & Volatility
Evenly matched — ALKS and HYFM each lead in 1 of 2 comparable metrics.
Risk & Volatility
HYFM is the less volatile stock with a 0.73 beta — it tends to amplify market swings less than BGMS's 1.88 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 99.6% from its 52-week high vs BGMS's 14.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.88x | 1.26x | 1.00x | 1.15x | 0.73x |
| 52-Week HighHighest price in past year | $6.70 | $26.18 | $38.45 | $2.40 | $4.78 |
| 52-Week LowLowest price in past year | $0.73 | $7.53 | $25.17 | $0.87 | $0.81 |
| % of 52W HighCurrent price vs 52-week peak | +14.0% | +76.4% | +99.6% | +57.1% | +20.9% |
| RSI (14)Momentum oscillator 0–100 | 39.4 | 50.3 | 60.0 | 63.9 | 47.6 |
| Avg Volume (50D)Average daily shares traded | 99K | 243K | 2.2M | 486K | 42K |
Analyst Outlook
HYFM leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: DBVT as "Buy", ALKS as "Buy". Consensus price targets imply 131.7% upside for DBVT (target: $46) vs 20.1% for ALKS (target: $46).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | — | — |
| Price TargetConsensus 12-month target | — | $46.33 | $46.00 | — | — |
| # AnalystsCovering analysts | — | 15 | 28 | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | 0 | 0 | 0 | — | 1 |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.5% | +0.3% | 0.0% |
ALKS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). HYFM leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
BGMS vs DBVT vs ALKS vs GRWG vs HYFM: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is BGMS or DBVT or ALKS or GRWG or HYFM a better buy right now?
For growth investors, Alkermes plc (ALKS) is the stronger pick with -5.
2% revenue growth year-over-year, versus -89. 8% for Bio Green Med Solution, Inc. (BGMS). Alkermes plc (ALKS) offers the better valuation at 26. 8x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BGMS or DBVT or ALKS or GRWG or HYFM?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +70.
6%, compared to -99. 8% for Hydrofarm Holdings Group, Inc. (HYFM). Over 10 years, the gap is even starker: ALKS returned +3. 5% versus HYFM's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BGMS or DBVT or ALKS or GRWG or HYFM?
By beta (market sensitivity over 5 years), Hydrofarm Holdings Group, Inc.
(HYFM) is the lower-risk stock at 0. 73β versus Bio Green Med Solution, Inc. 's 1. 88β — meaning BGMS is approximately 156% more volatile than HYFM relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 76% for Hydrofarm Holdings Group, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — BGMS or DBVT or ALKS or GRWG or HYFM?
By revenue growth (latest reported year), Alkermes plc (ALKS) is pulling ahead at -5.
2% versus -89. 8% for Bio Green Med Solution, Inc. (BGMS). On earnings-per-share growth, the picture is similar: Bio Green Med Solution, Inc. grew EPS 92. 2% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BGMS or DBVT or ALKS or GRWG or HYFM?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -260. 7% for Bio Green Med Solution, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -279. 2% for BGMS. At the gross margin level — before operating expenses — BGMS leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BGMS or DBVT or ALKS or GRWG or HYFM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BGMS or DBVT or ALKS or GRWG or HYFM better for a retirement portfolio?
For long-horizon retirement investors, Hydrofarm Holdings Group, Inc.
(HYFM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 73)). Bio Green Med Solution, Inc. (BGMS) carries a higher beta of 1. 88 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HYFM: -99. 8%, BGMS: -84. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BGMS and DBVT and ALKS and GRWG and HYFM?
These companies operate in different sectors (BGMS (Healthcare) and DBVT (Healthcare) and ALKS (Healthcare) and GRWG (Consumer Cyclical) and HYFM (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.